Latest Articlesddd
Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and …
Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. …
RegenxBio License Agreement with Pfizer RegenxBio (RGNX) announced a license agreement with Pfizer (PFE). Under the terms of …
Amgen Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. …
Gilead Sciences Activities There is no doubt that Gilead Sciences (GILD) is doing whatever it takes to expand, …
Halozyme and argenx Collaboration argenx (ARGX) dosed the first subject in phase 1 clinical trial for the …
Seattle Genetics Stock Rallied Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and …
CiRA, Takeda & T-CiRA Less than five years ago the Center for iPS Cell Research and Application …
Gilead and Galapagos Global Research Collaboration Gilead Sciences (GILD) and Galapagos NV (GLPG) entered into a 10-year global …
Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib From Exelixis (EXEL) we …
Illumina Stock Dropped Following Their Preliminary Revenue Announcement Illumina (ILMN) stock dropped 16% following the firm's announcement …
The EC Granted Conditional Approval for Regeneron and Sanofi Product Libtayo for CSCC The European Commission (EC) …
Sangamo and Pfizer Gene Therapy SB-525 Resulted in a Sustained Increase in Factor VIII Levels in …
Gilead to File NDA for Filgotinib for Rheumatoid Arthritis Meeting with the U.S. Food and Drug …
Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics …
ImmunoGen’s Big Internal Changes ImmunoGen (IMGN) announced a radical impacting decision following the completion of an in-depth …
Atossa Genetics Promising News for Endoxifen Atossa Genetics (ATOS) has promising news from a Phase 2 trial …
Krystal Biotech Krystal Biotech (KRYS) is a gene therapy firm focused on developing topical intradermal therapeutics for rare …
AMAG Pharmaceuticals’ Vyleesi™ was Approved The U.S. Food and Drug Administration (FDA) approved AMAG Pharmaceuticals’ (AMAG) product …
Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
